Onco Actu du 23 octobre 2019

	1.1 BIOLOGIE - GÉNOME
At Annual Plenary Meeting, GA4GH Unveils New Standards for Genomic Data, Workflow Sharing [Genome Web] The five standards, developed as part of the GA4GH Connect five-year strategic plan, are Crypt4GH, Variation Representation, Phenopackets, Tool Registry Service API, and the Data Security Infrastructure Policy. They address issues in data security, cloud computing, phenotype and variant data exchange, and the ethical implications of personal data use.
	1.4 BIOLOGIE - TECHNOS, MODÈLES
The breast cancer ‘avatar’ mice that could help personalise treatment [Cancer Research UK] One downside is that these mice lack an immune system, which has a big impact on how cancers progress and respond to treatment. There’s a lot more to do, such as setting up a clinical trial to see if using the information on avatars will benefit patients.
David Liu unveils newest advancement in CRISPR tech: Prime editing [EndPoints] Liu described the new tech as a “search-and-replace” tool – essentially control F for the human genome. That’s probably overselling where the tech is today – Dow said they only tested it on four human cell types, leaving questions on how it will fare in the rest – but it gets at the potential.
	3.1 PRÉVENTION - TABAC
FDA grants first-ever modified risk orders to eight smokeless tobacco products [FDA] FDA concludes completely switching from cigarettes to these authorized products lowers certain health risks.
	3.1.1 PRÉVENTION - TABAC - E-CIGS
South Korea warns of 'serious risk' from vaping, considers sales ban [Reuters] Since smoking was banned indoors at places like restaurants and cafés in 2015, South Korea become less tolerant of smokers. But e-cigarettes have been gaining popularity in the country’s $16 billion tobacco market since 2017.
	4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
Precision Medicine: State of affairs, strategic insight, trends, and predictions for 2020 all revealed in Diaceutics’ 2019 Pharma Precision Medicine Readiness Report [Diaceutics] In this latest annual assessment of the state of Precision Medicine, Diaceutics calls on the Precision Medicine community to rethink the relationship between testing and treatment, and end the “siloed thinking that is denying patients access to the right tests and better treatments.”
Report Says Many Precision Drugs Will Launch in Coming Years But Unclear if They Will Reach Patients [Genome Web] After spending 15 years advising leading drugmakers on how to integrate diagnostics into their therapeutic development and commercialization efforts, Diaceutics is still seeing slow test adoption and a difficult reimbursement climate impeding patient access to precision drugs, in addition to poor physician education and testing guidelines lagging behind guidelines supporting the use of the drug.
	4.1 DÉP., DIAG. & PRONO. - PROSTATE
Worcester Polytechnic Institute Researcher is Creating a Safer, More Accurate Way to Detect Prostate Cancer [WPI] His ongoing work aims to create a robotic system that will detect and analyze three different indicators of prostate cancer: a 3D image of any mass; high levels of a protein produced by cancer cells; and tissue with low-oxygen levels caused by cancer growth.
	4.2 DÉP., DIAG. & PRONO. - GÉNOME
Sequencing Plays Role in Treating High Risk Pediatric Brain Tumors [University of Michigan] Authors concluded that when it comes to children with high risk brain tumors, comprehensive sequencing should be the standard of care – everywhere. The call to action on pediatric cancer treatment was published in high profile journal Neuro-Oncology.
	4.9 DÉP., DIAG. & PRONO. - SEIN
Aggressive Form of Breast Cancer Influenced by Dual Action of Genes and RNA [Georgetown University] The scientists discovered that women with TNBC had specific alterations in copies of their genes that directly influenced the expression of 17 miRNAs compared to women with other forms of breast cancer who did not have these alterations. They also found that the expression levels of the majority of these miRNAs were associated with the tumor’s clinical aggressiveness (advanced grade and stage).
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
BMS nets another Opdivo lung cancer win—but it still has to beat Merck's high bar [Fierce Pharma] Adding an extra drug into the mix will not only raise “the cost of therapy somewhat,” but also up toxicity levels. The commercial value of CM-9LA will therefore depend on the balance between the clinical benefit and the toxicity.
Bristol-Myers makes Opdivo pitch for frontline lung cancer with open label PhIII study [EndPoints] The results of CheckMate-227 suggested that Yervoy has activity in lung cancer when combined with Opdivo — but the data suggest that patients have to wait for some period of time for the benefit to manifest.
Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Reuters] Shares of the company rose 5% to $56 in premarket trading.
CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer [BMS] The company will complete a full evaluation of the CheckMate -9LA data and looks forward to presenting these results at an upcoming congress and sharing them with regulatory authorities.
	5.2.6 PHARMA - BIOTECH
Intrepida Bio uncloaks with $9.5M and anti-BAG3 cancer programs from Italy [Fierce Biotech] That funding will bankroll IND-enabling studies for antibodies that target BAG3 and its receptor IFITM-2, which normally plays a role in the immune response against viruses but is hijacked by tumors to create an environment that promotes their growth and thwarts attacks from the immune system.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
EMA Recommends Refusal of the Marketing Authorisation for Quizartinib [ESMO] It was developed for the treatment of patients with FLT3-ITD positive AML.
	5.5 ASCO
Patients With Chemotherapy-Induced Peripheral Neuropathy Experience Pain Reduction in a Pilot Study of Oncology Massage Treatment [ASCO] Patients with chemotherapy-induced peripheral neuropathy (CIPN) experience a sustained reduction in lower extremity pain up to six weeks after completion of massage treatment when they received an intensive therapy schedule of three massages per week.
Cancer Pain Predicted by Lower Anxiety and Depression, Higher Social Support [ASCO] This year’s Supportive Care in Oncology Symposium will include approximately 150 abstracts focusing on efforts to improve supportive care for patients with cancer.
	6.7.2 APPLIS
Roche launches NAVIFY Guidelines app to help clinicians easily access, personalise and document latest guidance for patients with the most common cancers [NCCN] App alerts entire oncology care team to updates, integrates most recent content in their decision making process and facilitates documentation of intended personalised care plan.
	6.8 COMMUNICATION
How one bit of medical jargon fuels public confusion about cancer treatments [Health News Review] Despite including the word “survival,” the term PFS doesn’t indicate how long patients will live. It’s generally defined as the time that it takes for tumors to grow beyond an arbitrary amount, or for new ones to appear on a scan. That metric doesn’t necessarily tell you anything about overall survival.